A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT04251416
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Endometrial Carcinoma
Interventions
DRUG:
Sacituzumab Govitecan
Sponsor
Yale University
Collaborators
[object Object]